Langer-GouldAPopatRAHuangSM. Clinical and demographic predictors of long-term disability in patients with relapsing–remitting multiple sclerosis a systematic review. Arch Neurol2006; 63: 1686–1691.
2.
ScottTFSchramkeCJ. Poor recovery after the first two attacks of multiple sclerosis is associated with poor outcome five years later. J Neurol Sci2010; 292: 52–56.
3.
LublinFDBaierMCutterG. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology2003; 61: 1528–1532.
4.
SkoogBTedeholmHRunmarkerB. Continuous prediction of secondary progression in the individual course of multiple sclerosis. Mult Scler Relat Disord2014; 3: 584–592.
5.
Paz SoldánMMNovatnaMAbou ZeidN. Relapses and disability accumulation in progressive multiple sclerosis. Neurology2015; 84: 81–88.
6.
ScalfariANeuhausADegenhardtA. The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability. Brain2010; 133: 1914–1929.
7.
TremlettHYousefiMDevonshireV. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology2009; 73:1616–1623.
8.
ScottTFYouXFouldsP. Functional system scores provide a window into disease activity occurring during a multiple sclerosis treatment trial. Neurol Res2011; 33: 549–552.
9.
KalcinikTBuzzardKJokubaitisV. Risk of relapse phenotype recurrence in multiple sclerosis. Mult Scler J2014; 20: 1511–1522.
10.
GettingsEJHackettCTSchramkeCJ. Specific clinical phenotypes of relapsing multiple sclerosis based on disease activity. Mult Scler2014: 20(S1): P373.
11.
BejaouiKRolakLA. What is the risk of permanent disability from a multiple sclerosis relapse?Neurology2010; 74: 900–902.
12.
LublinFDReingoldSCCohenJA. Defining the clinical course of multiple sclerosis. Neurology2014; 83: 278–286.
13.
LublinFDCutterGGiovannoniG. Natalizumab reduces relapse clinical severity and improves relapse recovery in MS. Mult Scler Relat Disord2014; 2: 705–711.
EULAR/ACR collaborative recommendations. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthrit Care Res2008; 59: 1371–1377.
16.
LublinFD. Relapses do not matter in relation to long-term disability: no (they do). Mult Scler2011; 17: 1415–1516.
17.
ProsperiniLMancinelliCRDe GiglioL. Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis. Mult Scler J2014; 20(5): 566–576.
